Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Placebo Controlled, Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Neuropathic Pain

Next Previous
X
Search
Trial Profile

A Double Blind, Placebo Controlled, Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Neuropathic Pain

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XT-150 (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Xalud Therapeutics

    • Most Recent Events

    • 19 Jan 2023 Status changed from recruiting to discontinued.
    • 23 May 2022 Planned number of patients changed from 48 to 32.
    • 23 May 2022 The primary endpoints Incidence of TEAE and Visual Analog Scale of Pain Intensity were changed to Number of participants with TEAE and SAE, abnormal vital signs, clinically significant abnormal physical examination findings, anti-interleukin (IL)-10 antibodies and Protein, abnormal clinical and hematology parameters, plasmid DNA present in whole blood, and cytokines in Cerebrospinal fluid, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top